IS2036B - Lyfjablanda á formi dropalausnar sem inniheldur skammvirkt kalsíummótlyf af tvíhýdrópýridíngerð semvinna gegn háþrýstingi - Google Patents

Lyfjablanda á formi dropalausnar sem inniheldur skammvirkt kalsíummótlyf af tvíhýdrópýridíngerð semvinna gegn háþrýstingi

Info

Publication number
IS2036B
IS2036B IS4224A IS4224A IS2036B IS 2036 B IS2036 B IS 2036B IS 4224 A IS4224 A IS 4224A IS 4224 A IS4224 A IS 4224A IS 2036 B IS2036 B IS 2036B
Authority
IS
Iceland
Prior art keywords
short
antidote
dihydropyridine
antidepressant
solution containing
Prior art date
Application number
IS4224A
Other languages
English (en)
Other versions
IS4224A (is
Inventor
Hjalmar Andersson Kjell
Christina Byröd Eva
Hansson Anna-Carin
Nordlander Margareta
Christer Westerlund Rolf
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS4224A publication Critical patent/IS4224A/is
Publication of IS2036B publication Critical patent/IS2036B/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IS4224A 1993-11-12 1994-10-21 Lyfjablanda á formi dropalausnar sem inniheldur skammvirkt kalsíummótlyf af tvíhýdrópýridíngerð semvinna gegn háþrýstingi IS2036B (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9303744A SE9303744D0 (sv) 1993-11-12 1993-11-12 Pharmaceutical emulsion

Publications (2)

Publication Number Publication Date
IS4224A IS4224A (is) 1995-05-13
IS2036B true IS2036B (is) 2005-08-15

Family

ID=20391731

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4224A IS2036B (is) 1993-11-12 1994-10-21 Lyfjablanda á formi dropalausnar sem inniheldur skammvirkt kalsíummótlyf af tvíhýdrópýridíngerð semvinna gegn háþrýstingi

Country Status (30)

Country Link
US (1) US5739152A (is)
EP (1) EP0727997B1 (is)
JP (1) JP3759951B2 (is)
KR (1) KR100345627B1 (is)
CN (1) CN1072934C (is)
AT (1) ATE213158T1 (is)
AU (1) AU678650B2 (is)
CA (1) CA2176360C (is)
CZ (1) CZ290772B6 (is)
DE (1) DE69429871T2 (is)
DK (1) DK0727997T3 (is)
EE (1) EE03223B1 (is)
EG (1) EG20764A (is)
ES (1) ES2172572T3 (is)
FI (1) FI116999B (is)
HU (1) HU223142B1 (is)
IL (1) IL111345A (is)
IS (1) IS2036B (is)
MY (1) MY121201A (is)
NO (1) NO314877B1 (is)
NZ (1) NZ276197A (is)
PL (1) PL181462B1 (is)
PT (1) PT727997E (is)
RU (1) RU2144358C1 (is)
SA (1) SA94150314B1 (is)
SE (1) SE9303744D0 (is)
SK (1) SK283271B6 (is)
UA (1) UA40633C2 (is)
WO (1) WO1995013066A1 (is)
ZA (1) ZA948180B (is)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
ES2216517T3 (es) * 1998-05-29 2004-10-16 Skyepharma Canada Inc. Composiciones de microcapsulas termoprotegidas y procedimiento para su esterilizacion terminal con vapor.
SE9804002D0 (sv) * 1998-11-23 1998-11-23 Astra Ab New manufacturing process
DE10036871A1 (de) 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
WO2002102311A2 (en) 2001-06-15 2002-12-27 Cornerstone Pharmaceuticals Nanoparticles for treating targeted tissues and cells
ES2528669T3 (es) * 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
PE20090700A1 (es) * 2007-03-29 2009-07-13 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
BRPI0809579B8 (pt) 2007-03-29 2021-05-25 Progenics Pharm Inc formas cristalinas e seus usos
PL2139890T3 (pl) * 2007-03-29 2014-11-28 Wyeth Llc Antagoniści obwodowych receptorów opioidowych i ich zastosowania
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
EP2320740B1 (en) * 2008-08-01 2014-03-26 The Medicines Company Pharmaceutical compositions of clevidipine and methods for producing low impurity concentrations of the same
MX2011001241A (es) * 2008-08-01 2011-08-03 Medicines Co Composiciones farmaceuticas y metodos para estabilizar las mismas.
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US9034389B2 (en) * 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
JP6081058B2 (ja) * 2009-03-19 2017-02-15 第一三共株式会社 包装により安定保存された固形製剤
CN101780036B (zh) * 2010-03-30 2011-11-16 武汉武药科技有限公司 丁酸氯维地平脂微球注射液及其制备方法
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
BR112013008601B1 (pt) 2010-10-12 2020-03-31 Chiesi Farmaceutici S.P.A. Formulações de emulsão de clevidipina contendo agentes antimicrobianos
CN102531998A (zh) * 2010-12-09 2012-07-04 天津药物研究院 α型多晶型丁酸氯维地平结晶、其制备方法、用途和药物组合物
CN102525918A (zh) * 2010-12-30 2012-07-04 天津药物研究院 一种丁酸氯维地平的脂肪乳注射液及其制备工艺
US20120213855A1 (en) * 2011-02-17 2012-08-23 Cima Labs Inc. Dosage forms for weakly ionizable compounds
BR112013025368A8 (pt) * 2011-04-01 2018-06-12 The Medicines Co Medicamento, método para preparar um medicamento útil para reduzir danos por derrame em um sujeito com derrame, método para preparar um medicamento útil para reduzir a pressão sanguínea e reduzir danos por derrame em um sujeito com derrame
EP2793833B1 (en) 2011-12-20 2020-06-24 Vyome Therapeutics Limited Topical oil composition for the treatment of fungal infections
CN110840890A (zh) 2012-10-26 2020-02-28 凯西制药公司 用于在心力衰竭中控制血压和减轻呼吸困难的方法
CN103110580B (zh) * 2013-02-20 2014-09-17 北京德立福瑞医药科技有限公司 丁酸氯维地平注射剂
CN105263525A (zh) * 2013-04-12 2016-01-20 维奥姆生物科学有限公司 抗微生物剂的组合物和制剂、它们的方法以及用于治疗微生物感染的方法
MX385243B (es) 2014-05-19 2025-03-14 The Medicines Co Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3315805A1 (de) * 1983-04-30 1984-11-08 Bayer Ag, 5090 Leverkusen Wirkstoffzubereitungen
DE3339236A1 (de) * 1983-10-28 1985-05-09 Bayer Ag Arzneimittelzubereitung
DE3515335C2 (de) * 1985-04-27 1995-01-26 Bayer Ag Arzneizubereitung enthaltend Dihydropyridine und Verfahren zu ihrer Herstellung
DE4217842A1 (de) * 1992-05-29 1993-12-02 Dietl Hans Calciumantagonisten enthaltende pharmazeutische Zubereitung zur intravenösen und intrakoronaren Applikation sowie Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
JP3759951B2 (ja) 2006-03-29
ES2172572T3 (es) 2002-10-01
HK1013261A1 (en) 1999-08-20
HU9601268D0 (en) 1996-07-29
US5739152A (en) 1998-04-14
NZ276197A (en) 1997-04-24
CN1072934C (zh) 2001-10-17
AU1037195A (en) 1995-05-29
MY121201A (en) 2006-01-28
CZ133896A3 (en) 1996-09-11
IL111345A0 (en) 1994-12-29
JPH09505045A (ja) 1997-05-20
EE03223B1 (et) 1999-10-15
ZA948180B (en) 1995-05-12
CA2176360C (en) 2005-08-23
CA2176360A1 (en) 1995-05-18
SK59796A3 (en) 1996-12-04
UA40633C2 (uk) 2001-08-15
PL181462B1 (pl) 2001-07-31
NO961898D0 (no) 1996-05-10
ATE213158T1 (de) 2002-02-15
FI961999A0 (fi) 1996-05-10
IL111345A (en) 2000-08-31
DE69429871D1 (de) 2002-03-21
NO314877B1 (no) 2003-06-10
EG20764A (en) 2000-01-31
EP0727997A1 (en) 1996-08-28
SA94150314B1 (ar) 2005-06-14
CN1136774A (zh) 1996-11-27
FI116999B (fi) 2006-05-15
WO1995013066A1 (en) 1995-05-18
DK0727997T3 (da) 2002-04-22
IS4224A (is) 1995-05-13
KR100345627B1 (ko) 2003-03-15
PL314263A1 (en) 1996-09-02
PT727997E (pt) 2002-07-31
RU2144358C1 (ru) 2000-01-20
EP0727997B1 (en) 2002-02-13
AU678650B2 (en) 1997-06-05
SE9303744D0 (sv) 1993-11-12
FI961999L (fi) 1996-05-10
CZ290772B6 (cs) 2002-10-16
HUT74474A (en) 1996-12-30
HU223142B1 (hu) 2004-03-29
SK283271B6 (sk) 2003-04-01
DE69429871T2 (de) 2002-08-22
NO961898L (no) 1996-06-25

Similar Documents

Publication Publication Date Title
IS2036B (is) Lyfjablanda á formi dropalausnar sem inniheldur skammvirkt kalsíummótlyf af tvíhýdrópýridíngerð semvinna gegn háþrýstingi
DZ1794A1 (fr) Nouvelle formule pharmaceutique.
ATE168268T1 (de) Behandlung von menschlichen retrovirus- infektionen mit 2',3'-dideoxyinosin
FI924553A0 (fi) Tiofensulfonamider anvaendbara som kolanhydrasinhibitorer
DE69331409D1 (de) Oral 1alpha-hydroxyprevitamin d
BG103552A (bg) Терапевтични средства
ES2102475T3 (es) Nuevas alquil-amidas heterociclicas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
NO870560L (no) Nytt farmasoeytisk preparat.
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
TR200101163T2 (tr) Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları
EP0683668A4 (en) PREPARATIONS AND METHODS FOR TRANSDERMAL DRUG ADMINISTRATION.
PT99435A (pt) Processo para a preparacao de derivados de amino-sulfonil-ureia e de composicoes farmaceuticas que os contem
GR890100833A (en) Process for the preparation of a compound with gastric inhibitopy effect
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
KR910007523A (ko) 과콜레스테린혈증, 과지방혈증 및 혈전색전증 질병 치료용 토코트리엔올
KR960703593A (ko) (R)-암로디핀에 의한 평활근 세포 이동의 억제 (Inhibition of Smooth Muscle Cell Migration by (R)-Amlodipine)
DK0706395T3 (da) Lægemiddel med analgetisk effekt med minimal bevægelsesblokade
DK0808306T3 (da) Hidtil ukendte pyridin- eller pyridazinderivater, fremgangsmåder til fremstilling deraf og lægemidler indeholdende disse fo
KR960700053A (ko) 방사선회복제로서 리루졸의 이용(application of riluzole as a radiorestorer)